91 related articles for article (PubMed ID: 2527227)
1. Role of thromboxane receptors in Forssman shock in guinea pigs.
Schumacher WA; Steinbacher TE; Allen GT; Ogletree ML
J Appl Physiol (1985); 1989 Jul; 67(1):44-51. PubMed ID: 2527227
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane receptor activation during bronchospasm induced by platelet-activating factor.
Schumacher WA; Steinbacher TE
J Lipid Mediat; 1991; 4(1):97-110. PubMed ID: 1832573
[TBL] [Abstract][Full Text] [Related]
3. Role of thromboxane receptor activation in the bronchospastic response to endothelin.
Schumacher WA; Steinbacher TE; Allen GT; Ogletree ML
Prostaglandins; 1990 Jul; 40(1):71-9. PubMed ID: 2143841
[TBL] [Abstract][Full Text] [Related]
4. Protamine-induced pulmonary hypertension in heparinized monkeys and pigs is inhibited by the thromboxane receptor antagonist SQ 30,741.
Schumacher WA; Heran CL; Ogletree ML
Eicosanoids; 1990; 3(2):87-93. PubMed ID: 2144979
[TBL] [Abstract][Full Text] [Related]
5. Interference of levamisole with Forssman shock.
Casacó A; Carvajal D; Friman M; Noa M
Thromb Res; 1990 Aug; 59(3):629-37. PubMed ID: 2237831
[TBL] [Abstract][Full Text] [Related]
6. The effect of three novel thromboxane A2 receptor antagonists (S-1452, AA-2414 and ONO-3708) on the increase in pulmonary pressure caused by Forssman anaphylaxis in guinea-pigs.
Nagai H; Kumimoto M; Yoshitake K; Iwama T; Arimura A; Koda A
Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):233-8. PubMed ID: 1534171
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Forssman-induced bronchospasm and their inhibition.
Butler KD; Smith JR
Br J Pharmacol; 1981 May; 73(1):25-32. PubMed ID: 7284697
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
Basta M; Kirshbom P; Frank MM; Fries LF
J Clin Invest; 1989 Dec; 84(6):1974-81. PubMed ID: 2687331
[TBL] [Abstract][Full Text] [Related]
9. [Increase in pulmonary resistance induced by Forssman antiserum in guinea pigs].
Nakagami K; Kobayashi T; Takayanagi N; Yano J; Miura M
Nihon Yakurigaku Zasshi; 1983 Dec; 82(6):429-41. PubMed ID: 6607868
[TBL] [Abstract][Full Text] [Related]
10. An ultrastructural analysis of the vascular damage in the lethal and sublethal Forssman reaction in the guinea-pig.
Baker JR; Bullock GR; Butler KD; Williamson IH; White AM
Br J Exp Pathol; 1985 Dec; 66(6):709-18. PubMed ID: 3878720
[TBL] [Abstract][Full Text] [Related]
11. Role of thromboxane (Tx) A2 in guinea pig Forssman shock and the effect of OKY-046, Tx A2 synthetase inhibitor.
Nagai H; Yakuo I; Inagaki N; Koda A; Hamano S; Ujiie A; Nakazawa M
Prostaglandins Leukot Med; 1987 Feb; 26(2):133-41. PubMed ID: 3470814
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of Forssman antibodies in in vitro perfusion experiments.
Chen H; Diakun KR; Milgrom F
Immunol Commun; 1984; 13(6):571-6. PubMed ID: 6335882
[TBL] [Abstract][Full Text] [Related]
13. Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys.
Schumacher WA; Heran CL; Goldenberg HJ; Harris DN; Ogletree ML
Am J Physiol; 1989 Mar; 256(3 Pt 2):H726-34. PubMed ID: 2522282
[TBL] [Abstract][Full Text] [Related]
14. [Anti-allergic effects of (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046), a specific thromboxane (TX) A2 synthetase inhibitor: effect of OKY-046 on II-IV type allergic reactions].
Kikuchi S; Takehana Y; Hamano S; Ichikawa K; Komatsu H; Okegawa T; Ikeda S
Nihon Yakurigaku Zasshi; 1990 Mar; 95(3):131-7. PubMed ID: 2141317
[TBL] [Abstract][Full Text] [Related]
15. Effect of thromboxane receptor antagonists on venous thrombosis in rats.
Schumacher WA; Heran CL
J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985
[TBL] [Abstract][Full Text] [Related]
16. Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
Grover GJ; Schumacher WA
J Pharmacol Exp Ther; 1989 Feb; 248(2):484-91. PubMed ID: 2521899
[TBL] [Abstract][Full Text] [Related]
17. Activity of the short-acting thromboxane receptor antagonist, SQ 30,741, in thrombolytic and vasospastic models in monkeys.
Schumacher WA; Heran CL; Hartl KS; Ogletree ML
J Pharmacol Exp Ther; 1990 May; 253(2):841-6. PubMed ID: 2140131
[TBL] [Abstract][Full Text] [Related]
18. Effects of 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3- (1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid with thromboxane A2 synthetase inhibitory and H1-blocking activities on anaphylactic bronchospasm.
Nakamura S; Shirahase H; Kanda M; Wada K; Kamiya S; Matsui H; Kurahashi K
Arzneimittelforschung; 1996 Nov; 46(11):1067-71. PubMed ID: 8955866
[TBL] [Abstract][Full Text] [Related]
19. Effect of the thromboxane A2-receptor antagonists, SQ 29,548 and SQ 28,668, on the pulmonary hypertensive response to endotoxemia in swine.
Schumacher WA; Adams HD; Ogletree ML
Pharmacology; 1987; 34(6):301-8. PubMed ID: 2958886
[TBL] [Abstract][Full Text] [Related]
20. The cardioprotective effects of the thromboxane receptor antagonist SQ 30,741 are not reversed by aspirin.
Grover GJ; Parham CS; Schumacher WA
Basic Res Cardiol; 1991; 86(2):99-106. PubMed ID: 1831610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
